Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, August 1st. Analysts expect the company to announce earnings of $0.27 per share for the quarter.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.23 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.28 by $0.05. The business had revenue of $56.30 million for the quarter, compared to analyst estimates of $54.15 million. Sucampo Pharmaceuticals had a return on equity of 43.27% and a net margin of 11.36%. The firm’s revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.21 EPS. On average, analysts expect Sucampo Pharmaceuticals to post $1.01 EPS for the current fiscal year and $1.04 EPS for the next fiscal year.

Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) opened at 11.00 on Tuesday. Sucampo Pharmaceuticals, Inc. has a 52 week low of $9.30 and a 52 week high of $17.55. The firm’s 50-day moving average price is $10.44 and its 200 day moving average price is $10.82. The firm has a market cap of $511.10 million, a P/E ratio of 18.33 and a beta of 1.46.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at

A number of analysts have recently issued reports on SCMP shares. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Jefferies Group LLC set a $13.00 price target on Sucampo Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, April 20th. Mizuho reiterated a “buy” rating and set a $14.00 price target on shares of Sucampo Pharmaceuticals in a research report on Tuesday, April 4th. Maxim Group reiterated a “buy” rating and set a $21.00 price target on shares of Sucampo Pharmaceuticals in a research report on Thursday, April 13th. Finally, ValuEngine upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $17.00.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Earnings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.